Iron overload in myelodysplastic syndromes (MDS)
- 25 November 2017
- journal article
- research article
- Published by Springer Science and Business Media LLC in International Journal of Hematology
- Vol. 107 (1), 55-63
- https://doi.org/10.1007/s12185-017-2367-1
Abstract
Iron overload (IOL) starts to develop in MDS patients before they become transfusion-dependent because ineffective erythropoiesis suppresses hepcidin production in the liver and thus leads to unrestrained intestinal iron uptake. However, the most important cause of iron overload in MDS is chronic transfusion therapy. While transfusion dependency by itself is a negative prognostic factor reflecting poor bone marrow function, the ensuing transfusional iron overload has an additional dose-dependent negative impact on the survival of patients with lower risk MDS. Cardiac dysfunction appears to be important in this context, as a consequence of chronic anemia, age-related cardiac comorbidity, and iron overload. Another potential problem is iron-related endothelial dysfunction. There is some evidence that with increasing age, high circulating iron levels worsen the atherosclerotic phenotype. Transfusional IOL also appears to aggravate bone marrow failure in MDS, through unfavorable effects on mesenchymal stromal cells as well a hematopoietic cells, particularly erythroid precursors. Patient series and clinical trials have shown that the iron chelators deferoxamine and deferasirox can improve hematopoiesis in a minority of transfusion-dependent patients. Analyses of registry data suggest that iron chelation provides a survival benefit for patients with MDS, but data from a prospective randomized clinical trial are still lacking.Keywords
This publication has 62 references indexed in Scilit:
- Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNetBlood, 2013
- Hematologic responses to deferasirox therapy in transfusion-dependent patients with myelodysplastic syndromesHaematologica, 2012
- Hepcidin Levels and Their Determinants in Different Types of Myelodysplastic SyndromesPLOS ONE, 2011
- Cardiac iron overload in transfusion‐dependent patients with myelodysplastic syndromesBritish Journal of Haematology, 2011
- Impact of the degree of anemia on the outcome of patients with myelodysplastic syndrome and its integration into the WHO classification-based Prognostic Scoring System (WPSS)Haematologica, 2011
- On T2* Magnetic Resonance and Cardiac IronCell Metabolism, 2011
- Uptake of Non-Transferrin Iron by Erythroid CellsAnemia, 2010
- Improved Survival in Patients with Myelodysplastic Syndrome Receiving Iron Chelation TherapyClinical Leukemia, 2008
- Quantification by magnetic resonance imaging and liver consequences of post-transfusional iron overload alone in long-term survivors after allogeneic hematopoietic stem cell transplantationHaematologica, 2007
- Enhanced growth of myelodysplastic colonies in hypoxic conditionsExperimental Hematology, 2007